Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 2/3 1Phase 2 1

Status

Recruiting 1Not yet recruiting 1Completed 1

Sponsor Class

OTHER_GOV 1OTHER 1INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 3Thoracic 1Head & Neck 1Gynecologic 1Breast 1

Conditions

Carcinoma, Hepatocellular 2Pancreatic Neoplasms 1

Interventions

Specimen Handling 80Fluorouracil 74Oxaliplatin 69Magnetic Resonance Spectroscopy 61Leucovorin 58Gemcitabine 55Bevacizumab 55Biopsy 41Capecitabine 40Irinotecan 37Cisplatin 36Nivolumab 35pembrolizumab 33Cetuximab 33durvalumab 30Paclitaxel 27130-nm albumin-bound paclitaxel 27atezolizumab 20Folfox protocol 20Radiotherapy 17Carboplatin 17dehydroftorafur 15Taxes 15Cyclophosphamide 15fludarabine 13X-Rays 13Radiation 13trastuzumab deruxtecan 12Surgical Procedures, Operative 12Albumin-Bound Paclitaxel 12

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
camrelizumab × Gastrointestinal × 30 days × Clear all
NCT07618546 2026-06-01

A Multicenter, Randomized, Open-label, Controlled Study of HAIC Combined With Camrelizumab and Apatinib Mesylate for Perioperative Treatment of Resectable Hepatocellular Carcinoma With High-risk Recurrence Factors

Henan Cancer Hospital

Phase NA Not yet recruiting
208 enrolled
Gastrointestinal

Carcinoma, Hepatocellular

NCT06361888 2026-05-28

A Phase II/III Trial to Evaluate the Efficacy and Safety of Surufatinib Combined With Camrelizumab, Nab-paclitaxel, and Gemcitabine in Metastatic Pancreatic Cancer

Hutchmed

Phase 2/3 Recruiting
502 enrolled
Gastrointestinal

Pancreatic Neoplasms

NCT05099848 2026-05-22

A Trial of Conversion Treatment of HAIC Combined With Camrelizumab and Apatinib for Unresected Hepatocellular Carcinoma

Shandong Cancer Hospital and Institute

Phase 2 Completed
21 enrolled
Gastrointestinal

Carcinoma, Hepatocellular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡